The Human Parkinsome

OccamzRazor is building the first ever complete map of a disease — in this case, Parkinson’s disease. It allows us to understand how the disease works, identify biomarkers, develop new therapeutic targets and evaluate the effectiveness of treatments. With this map, we will be able to navigate the intricacies of the brain and reveal new hidden connections to find the quickest path to a cure.

The Human Parkinsome is OccamzRazor’s proprietary multi-dimensional knowledge map



Firstly, we do not know all that we could know. There are millions of pages of research unread
and uncorrelated — far too much data for people to handle.

Secondly, drug discovery has been driven by a one-size-fits-all model that fails to reflect the complex interactions that take place inside
the human brain.

 We set our focus on Parkinson’s disease, which affects about 10 million people worldwide. In addition to the toll in human suffering, Parkinson’s costs the U.S. economy alone $25 billion a year. It is one of the most difficult problems of systems biology, one that will not be solved by a single target approach but requires understanding and fixing of the diseased brain as a whole.  This complexity makes it the ideal target
for artificial intelligence (AI). 

In order to produce results, we have overcome major technological obstacles in AI. We regularly publish our solutions in the highest
ranking publication outlets and conferences, such as ACL and NIPS, while also developing intellectual property.

The Human Parkinsome draws from all domains of knowledge around Parkinson’s disease and uncovers new connections


Our Approach

 “Labeled training data is the new new oil.” 
Christopher Ré, Stanford

Together, with world leading experts from Stanford University, we developed a data labeling system to vastly accelerate
the generation of Natural Language Processing (NLP) specific datasets used to train AI for Parkinson’s specific tasks.

OccamzRazor’s Natural Language Processing (NLP) pipeline reasons from text and uses the wealth of scientific literature to inform the Human Parkinsome

Building on this technology, we developed a proprietary platform that utilizes AI to learn from all available data and transforms this into machine-readable graphs; The Human Parkinsome comprises scientific literature, patents, medical trials, electronic medical records (EMRs), genomics, proteomics, and preclinical data. 

Furthermore, we have recently shown in a proof-of-concept publication that knowledge graphs like the Human Parkinsome can even be used to deepen our understanding of other complex domains such as chess.

William of Ockham banner-01.png


The Human Parkinsome is a multi-dimensional knowledge graph that contains the relationships between all the information we have on Parkinson’s and related diseases (e.g. Gaucher’s disease). For the first time, we link the information from doctor visits to genetic profiles of individual patients and molecular mechanisms in the brain to clinical drug trial data and more. It resembles a digital scientist who knows all research, patients,
and clinical trials and comes up with novel approaches based on that knowledge.

This is an improvement over existing, one-dimensional approaches limited to singular types of data, like genomics.
Creating context for data is critical to curing complex diseases.

 We are using the Human Parkinsome to train AI that can suggest systematic strategies for a Parkinson’s cure in various patient subgroups.

The Human Parkinsome offers new unique insights into the disease which are used to solve pressing issues, such as finding a cure

Together with our partners we keep pushing the boundaries of technology to give hope to millions of patients and their families and develop the first treatments to cure Parkinson’s disease. Our first pre-clinical experiments for AI generated treatments are currently in the planning stage.


Executive Team

OccamzRazor is an international assembly of biomedical scientists, bioinformaticians and AI experts. We value team spirit, humility, and constant learning. Since we come from various industrial and academic avenues, we foster a culture of constant exchange and mutual support to achieve our ambitious goals together.

Katarina Example.png

Dr. Katharina Sophia Volz

CEO and founder

She was Stanford University's first PhD in Stem Cell Biology & Regenerative Medicine, earning her degree in just two and a half years. Dr. Volz has been doing biomedical research for the last 16 years and was listed on Forbes 30u30 (Science) in 2017. She has been awarded multiple fellowships and awards doing research in labs at 10 prestigious institutions around the world, including: Harvard, UCLA, HHMI, Ohio State, TU Graz and Stanford University.

Berk Kapicoglu.png

Dr. Berk Kapicioglu

Head of AI

Dr. Kapicioglu joined OccamzRazor from Foursquare Labs, where he was their head of machine learning. Prior to that, he worked at Google and the location intelligence startup Sense Networks. He received his PhD from the computer science department at Princeton University, and his BA from the computer science, mathematics, and philosophy departments at the University of Pennsylvania. His work has been published at venues such as AISTATS, UAI, IJCAI, RecSys, and NIPS.

Martin Bringmann.png

Dr. Martin Bringmann

Head of Science

He received his Master's in Biochemistry and Molecular Biology from Potsdam University, after which Dr. Bringmann received his PhD in Molecular Biology from the Max Planck Institute. This was followed by a postdoctoral fellowship in the Department of Biology at Stanford University. Dr. Bringmann has been awarded fellowships from the European Molecular Biology Organization (EMBO) and the German Research Foundation (DFG), and is co-author of 14 publications.

Tarik Koc.png

Tarik Koc

Head of Engineering

After cutting his teeth as an engineering intern at SAS Institute, Tarik became a patent examiner at the United States Patent and Trademark Office. He went on to help bootstrap HeartIT, Infina Connect, and Yieldmo where he was an early engineer at start-ups in the domain of Cardiac MRI, EMR, and ad-tech respectively.

Mr. Koc received his BS in Computer Science with emphasis on Computational Biology from Virginia Tech.


Scientific and Industrial Advisors

OccamzRazor is proud to draw on the experience and expertise of some of the sharpest minds in both medical science and AI.
Our advisors are leaders in all aspects of our business and support us with key insight.


Prof. Ed Boyden, PhD

Renowned Neuroscience Professor at MIT Media Lab; Winner Breakthrough Prize

Alexander Levy

Co-founder of AI drug-discovery company Atomwise

Phil Libin

Co-founder & former long-term CEO of Evernote,
CEO at AI firm All Turtles

Shameer Kader, PhD

Experienced computational biologist with a decade of relevant industry experience

Prof. Agnieszka Czechowicz, MD, PhD

Co-founded 6 Biotech companies, including Editas;
VC at Third Rock


Carrolee Barlow, MD, PhD

Renowned Parkinson’s expert;
CEO Parkinson’s Institute & Clinical Center

Milind Kamkolkar

CDO Sanofi; previous Global Head of Data Science Novartis

Tom Glocer, JD

Former long-term CEO of Thompson Reuters

Nicole Shanahan, JD

Patent attorney and CEO of ClearAccessIP

Danny Moses

Wall Street insider and investor




The Michael J. Fox
for Parkinson’s Research

Sergey Brin Family Foundation.png

Nicole Shanahan &
Sergey Brin
Family Foundation



OccamzRazor is always looking to push the boundaries of medical research and to find solutions to complex disease areas.

If you would like to keep up to date with our latest developments, please visit News & Updates and sign up below to join our mailing list.

You can find OccamzRazor on social media here:



This is a very exciting time for OccamzRazor. We are expanding rapidly and looking for people who want to share the journey.
Our internal culture is open and collaborative, we’re creating a space everyone can feel proud to contribute to.

Currently, we have a range of openings, but we are also happy to welcome speculative applications.

Current vacancies


 get in touch

As a forward looking company, we know that to retain our competitive edge we will form new partnerships and gain new investment in the future.

If you would like to make a preliminary enquiry or get in touch with our team please use the link below.